SEC Comment Letter 0000000000-24-013351 to Marker Therapeutics, Inc. (MRKR) (CIK 0001094038) (MRKR)
Marker Therapeutics, Inc. (MRKR) (CIK 0001094038)
Date: Dec. 4, 2024 · CIK: 0001094038 · Accession: 0000000000-24-013351
AI Filing Summary & Sentiment
File numbers found in text: 333-283512
Letter
December 4, 2024 Juan Vera Chief Executive Officer Marker Therapeutics, Inc. 2450 Holcombe Blvd Suite BCM-A, MS: BCM251 Houston, TX 77021 Re:Marker Therapeutics, Inc. Registration Statement on Form S-3 Filed November 27, 2024 File No. 333-283512 Dear Juan Vera: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Mark A. Catchur
Show Raw Text
December 4, 2024
Juan Vera
Chief Executive Officer
Marker Therapeutics, Inc.
2450 Holcombe Blvd
Suite BCM-A, MS: BCM251
Houston, TX 77021
Re:Marker Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 27, 2024
File No. 333-283512
Dear Juan Vera:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Mark A. Catchur